LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1 USD -8.26%
Market Cap: 26.3m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LAVA Therapeutics NV
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Cash from Financing Activities
-$571k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Cash from Financing Activities
-$33.2m
CAGR 3-Years
-19%
CAGR 5-Years
9%
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Cash from Financing Activities
-€2.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Cash from Financing Activities
-$52.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Cash from Financing Activities
$1.3B
CAGR 3-Years
5%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Cash from Financing Activities
$487.4m
CAGR 3-Years
36%
CAGR 5-Years
123%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
26.3m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.18 USD
Undervaluation 54%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Cash from Financing Activities?
Cash from Financing Activities
-571k USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Cash from Financing Activities amounts to -571k USD.

Back to Top